Anika Therapeutics, Inc.
Financials
Valuation Metrics
Anika Therapeutics, Inc.'s Market Cap is $258M. At end of 2025 it was $137M. Ranked #2917 of 3,114 in US market (top 94%), #1315 of 1,469 on NASDAQ (top 90%), #182 of 203 in Health Care Equipment & Services (top 90%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $258M | US#2,917/3,114 Sec#182/203 |
| Revenue | $121M | US#2,640/3,114 Sec#178/203 |
| Net Income | $-4M | US—/3,114 Sec—/203 |
| Total Assets | $183M | US#2,999/3,114 Sec#189/203 |
| Net Assets | $137M | US#2,758/3,114 Sec#171/203 |
| Employees | 235 | US#2,454/3,114 Sec#168/203 |
| Value | ||
| P/B | 1.88x | US#1,300/3,114 Sec#57/203 |
| P/S | 2.14x | US#1,432/3,114 Sec#95/203 |
| EV/EBITDA | 89.45x | US#2,425/3,114 Sec#134/203 |
| FCF Yield | 0.22% | US#2,245/3,114 Sec#139/203 |
| Profitability | ||
| ROE | -2.76% | US#2,197/3,114 Sec#120/203 |
| ROA | -2.06% | US#2,378/3,114 Sec#129/203 |
| Op. Margin | -4.24% | US#2,438/3,114 Sec#144/203 |
| Revenue Growth | 5.33% | US#1,731/3,114 Sec#129/203 |
| Financial Health | ||
| Debt Ratio | 33.65% | US#380/3,114 Sec#38/203 |
| Total Debt | $23M | US#2,731/3,114 Sec#170/203 |
| FCF | $562000.00 | US#2,282/3,114 Sec#142/203 |
| Cash | $38M | US#2,679/3,114 Sec#172/203 |
| Current Ratio | 4.48x | US#531/3,114 Sec#49/203 |
| Net Debt/EBITDA | -5.56x | US#64/3,114 Sec#7/203 |
| Performance | ||
| 1Y Return | 98.97% | US#100/3,114 Sec#16/203 |
| 1M Return | 1.57% | US#1,334/3,114 Sec#130/203 |
| From 52W High | -15.21% | US#622/3,114 Sec#59/203 |
| 1Y MDD | -22.56% | US#807/3,114 Sec#20/203 |
| Trading | ||
| Volume | 84,309 shares | US#3,028/3,114 Sec#201/203 |
| Trading Value | $2M | US#2,979/3,114 Sec#189/203 |
| Per Share | ||
| EPS | $-0.28 | US—/3,114 Sec—/203 |
| BPS | $10.32 | US#1,815/3,114 Sec#104/203 |
Company Info
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.